Driehaus Capital Management LLC Invests $2.39 Million in Surrozen, Inc. $SRZN

Driehaus Capital Management LLC bought a new position in shares of Surrozen, Inc. (NASDAQ:SRZN) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 204,934 shares of the company’s stock, valued at approximately $2,390,000. Driehaus Capital Management LLC owned about 0.06% of Surrozen at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Surrozen by 26.1% during the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock worth $321,000 after purchasing an additional 4,630 shares during the last quarter. Heights Capital Management Inc. acquired a new position in shares of Surrozen during the 1st quarter worth approximately $524,000. Trustees of Columbia University in the City of New York acquired a new position in shares of Surrozen during the 4th quarter worth approximately $688,000. Stonepine Capital Management LLC boosted its holdings in shares of Surrozen by 24.7% during the 4th quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock worth $1,969,000 after purchasing an additional 27,200 shares during the last quarter. Finally, Vivo Capital LLC acquired a new position in shares of Surrozen during the 1st quarter worth approximately $3,032,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Surrozen in a report on Monday, May 12th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $38.50.

Surrozen Stock Performance

SRZN opened at $12.19 on Friday. Surrozen, Inc. has a one year low of $5.90 and a one year high of $18.17. The stock has a market capitalization of $104.47 million, a PE ratio of -0.85 and a beta of 0.60. The business’s 50 day moving average price is $9.64 and its 200 day moving average price is $9.87.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Friday, August 8th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.09. Surrozen had a negative return on equity of 545.43% and a negative net margin of 274.42%.The firm had revenue of $0.98 million for the quarter. As a group, equities research analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.